GILL JOHN 4
4 · Altimmune, Inc. · Filed Apr 6, 2026
Research Summary
AI-generated summary of this filing
Altimmune (ALT) Director John Gill Buys 9,200 Shares
What Happened John Gill, a director of Altimmune, purchased 9,200 shares in an open-market/private purchase reported on April 6, 2026. The reported weighted-average price was $3.41 per share, for a total purchase value of approximately $31,350. This is a purchase (insider buy), which investors often view as a sign of confidence by the insider, though it does not prove future performance.
Key Details
- Transaction date: 2026-04-06 (reported same day; filing appears timely)
- Transaction type/code: Open market or private purchase (Code P)
- Shares purchased: 9,200
- Price: weighted average $3.41; actual trade prices ranged from $3.4050 to $3.4080 (footnote)
- Total consideration: ~$31,350
- Shares owned after transaction: Not specified in the provided filing excerpt
- Footnote: Reporting person will provide, upon request, the number of shares bought at each individual price within the stated range
Context
- Purchases by directors are factual signals of personal investment but are not definitive predictions of company performance.
- The filing discloses a weighted-average price and multiple underlying transactions; the reporting person offers to supply a per-trade breakdown to investors or SEC staff if requested.
Insider Transaction Report
Form 4
GILL JOHN
Director
Transactions
- Purchase
Common Stock, par value $0.0001
[F1]2026-04-06$3.41/sh+9,200$31,350→ 21,700 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4050 to $3.4080, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Signature
/s/ Gregory Weaver, as Attorney-in-Fact|2026-04-06